US20070248683A1 - Novel Compositions of Fat-Soluble Substances - Google Patents

Novel Compositions of Fat-Soluble Substances Download PDF

Info

Publication number
US20070248683A1
US20070248683A1 US11/659,509 US65950905A US2007248683A1 US 20070248683 A1 US20070248683 A1 US 20070248683A1 US 65950905 A US65950905 A US 65950905A US 2007248683 A1 US2007248683 A1 US 2007248683A1
Authority
US
United States
Prior art keywords
compositions
fat
substance
soluble
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/659,509
Inventor
Elger Funda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35427847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20070248683(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Assigned to DSM IP ASSETS B.V. reassignment DSM IP ASSETS B.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FUNDA, ELGER
Publication of US20070248683A1 publication Critical patent/US20070248683A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
    • A23D7/0053—Compositions other than spreads
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/179—Colouring agents, e.g. pigmenting or dyeing agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/70—Fixation, conservation, or encapsulation of flavouring agents
    • A23L27/72—Encapsulation
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A23L5/40—Colouring or decolouring of foods
    • A23L5/42—Addition of dyes or pigments, e.g. in combination with optical brighteners
    • A23L5/43—Addition of dyes or pigments, e.g. in combination with optical brighteners using naturally occurring organic dyes or pigments, their artificial duplicates or their derivatives
    • A23L5/44—Addition of dyes or pigments, e.g. in combination with optical brighteners using naturally occurring organic dyes or pigments, their artificial duplicates or their derivatives using carotenoids or xanthophylls
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
    • C09B67/0001—Post-treatment of organic pigments or dyes
    • C09B67/0004—Coated particulate pigments or dyes
    • C09B67/0008—Coated particulate pigments or dyes with organic coatings
    • C09B67/0013—Coated particulate pigments or dyes with organic coatings with polymeric coatings
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
    • C09B67/0097—Dye preparations of special physical nature; Tablets, films, extrusion, microcapsules, sheets, pads, bags with dyes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals

Definitions

  • the present invention relates to novel compositions of fat-soluble substances. More particularly, the present invention relates to novel powderous, water-soluble compositions of fat-soluble substances and aqueous solutions or emulsions thereof.
  • the novel compositions of this invention can be used as additives for food, beverages, animal feeds, cosmetics or drugs to incorporate said fat-soluble ingredients into such items.
  • a particular feature of the novel compositions is the encapsulation of the fat-soluble substance(s) to form an inner (discontinuous) phase within an outer (continuous) phase of a matrix substance.
  • the present invention relates to novel compositions comprising
  • the present invention relates to a process for the preparation of the novel compositions as defined above.
  • the present invention relates to food or animal feed or supplement therefore, or pharmaceutical or cosmetic formulations comprising a composition as defined above.
  • fat-soluble active ingredient denotes any physiologically active ingredient that is soluble in lipids and insoluble or sparingly soluble in water.
  • fat-soluble active ingredients are fat-soluble vitamins, viz., vitamin A, D, E and K and derivatives thereof such as vitamin A esters, e.g. vitamin A acetate and palmitate, and vitamin E esters, e.g.
  • carotenoids and carotenoid derivatives e.g., are ⁇ - or ⁇ -carotene, 8′-apo- ⁇ -carotenal, 8′-apo- ⁇ -carotenoic acid esters such as the ethyl ester, canthaxanthin, astaxanthin, astaxanthin esters, lycopene, lutein, zeaxanthin or crocetin and their derivatives; polyunsaturated fatty acids, e.g. eicosapentaenoic acid, docosahexaenoic acid, arachidonic acid and ⁇ -linolenic acid and/or ethylester.
  • carotenoids and carotenoid derivatives e.g., are ⁇ - or ⁇ -carotene, 8′-apo- ⁇ -carotenal, 8′-apo- ⁇ -carotenoic acid esters such as the ethyl ester, canthaxanthin,
  • encapsulating substance denotes any edible substance, that is solid at application temperature, able to encapsulate the active ingredient and soluble together with the active ingredient in one common solvent.
  • substances which are commonly used as coating materials. More preferably used are synthetic or natural waxes or wax-like substances, or natural or synthetic edible polymers.
  • the wax or wax-like substance is preferably selected from among e.g. carnauba wax, candelilla wax, beeswax, rice bran wax, sugar cane wax, japan wax, esparto grass wax, cork wax, guaruma wax, ouricury wax, montan wax, spermaceti, lanolin, hydrated jojoba wax or paraffin wax, fats, hydrogenated fats, fatty acid monoglycerides, polypropylene glycol, polyethylene glycol, fatty acid esters, sucrose fatty acid esters, fatty acids, hydrocarbons and hydrogenated products thereof.
  • Natural edible polymers are preferably selected from modified (e.g. alkylated) carbohydrates (e.g. starch, pectin, alginate, carrageenan, furcellaran, chitosan, maltodextrin, dextrin derivatives), celluloses and cellulose derivatives (e.g. cellulose acetate, methyl cellulose, hydroxypropyl methyl cellulose), gums or modified (e.g. alkylated) gums (e.g. gum arabic, gum xanthan, gum guar, gum ghatti, gum karaya, gum tragacanth, locust bean gum, gellan gum), resins (e.g. shellac, wood rosin, and tree resins such as copal, damar and elemi), zein. Modification of these polymers may be necessary to improve solubility in organic solvents.
  • modified (e.g. alkylated) carbohydrates e.g. starch, pectin, alginate
  • the synthetic polymer is preferably selected from among the synthetic waxes such as polyethylene and polypropylene waxes, coumarene-indene resins, polylactic acid (PLA) and poly(lactic/glycolic) acid (PLGA), acrylic polymers (methacrylic acid copolymers and ammonio methacrylate copolymers), polyorthoesters, polyphosphazenes, polyanhydrides, polyglycolide (PGA), poly( ⁇ -caprolactone), polydioxanone, trimethylene carbonate, poly( ⁇ -hydroxybutyrate), poly( ⁇ -ethyl glutamate), poly(DTH iminocarbonate), poly(bisphenol A iminocarbonate) and polycyanoacrylate, especially the acrylic polymers.
  • Polyvinyl alcohol and polyvinylpyrrolidone polymers may also be used.
  • Preferred encapsulating substances for use in the invention are beeswax, carnauba wax, paraffin wax, polyethylene glycol and hydrogenated fats.
  • the ratio between active ingredient and encapsulating substance is determined by the amount of encapsulating substance, necessary to protect the active ingredient and by the target content of active ingredient within the formulation. Ratio of active ingredient: encapsulating substance may vary between about 10:1 to about 1:20 preferably between 1:3 and 3:1.
  • Ratio of (active ingredients+encapsulating substances): matrix is selected according to requirements of the specific formulation. Typical ratios could be e.g. 1:99 (1% forms), 1:9 (10% forms) or 1:1 (50% forms). The amount of matrix is determined by the amount necessary to stabilise the emulsion and to encapsulate the inner (oily) phase.
  • Matrix components are preferably selected from among carbohydrates (e.g. cellulose, starch, modified starch, dextrin, pectin, alginate, carrageenan, furcellaran, chitosan), gums (e.g. gum arabic, gum xanthan, gum guar, gum ghatti, gum karaya, gum tragacanth, locust bean gum, gellan gum), proteins (e.g. fish, poultry and mammalian gelatine, soy protein, pea protein, zein (from corn) wheat gluten, lupin protein, peanut protein, milk proteins or hydrolysed or modified milk proteins, especially casein or whey proteins, lignins and lignin derivatives (e.g. lignosulfonates, kraft lignins), celluloses and cellulose derivatives (e.g. carboxymethyl cellulose, carboxyethyl cellulose, hydroxypropyl cellulose).
  • carbohydrates e.g. cellulose, star
  • Preferred matrix substances for use in the invention are gelatin, lignosulfonates, milk proteins or hydrolysed milk proteins, plant proteins or hydrolysed plant proteins, or modified starch, especially gelatine, casein and casein hydrolysates, soy protein, hydrolysates thereof, lignosulfonate, physically modified soy protein, starches and modified starches, especially octyl succinyl starch, pectins and carboxymethyl cellulose.
  • matrix substances which provide cold-water soluble compositions, such as lignosulfonate, fish gelatin, milk protein and hydrolysed plant proteins.
  • solvent any organic solvent or solvent combination may be used that is able to dissolve active ingredient and encapsulating substance.
  • Volatile Solvents and solvent combinations that are easy to evaporate from the emulsion are preferred. Examples for solvents are isopropanole, hexane, cyclohexane, acetone, methyl ethyl ketone, methylenchloride, chloroform, toluene, tetrahydrofurane, acetic acid ethyl ester.
  • compositions according to the invention comprise a matrix substance as a continuous phase wherein particles (droplets) of an encapsulating substance are distributed. Within said particles (droplets) of the encapsulating substance, the fat-soluble substance is distributed.
  • Such compositions are distinguished from compositions wherein particles of the fat-soluble substance are distributed within a matrix substance (see, e.g. EP 564 989) or compositions wherein the fat-soluble substance is coated with a coating material or compositions according to JP 2004196673 wherein carotenoid-containg solutions are emulsified with coating solutions and subsequent freeze-drying thus producing powders wherein active ingredient and coating agent are distributed in different phases of the emulsion.
  • the compositions of the present invention by virtue of their unique structure and mode of preparation provide superior stability on storage and application and show good bioavailability.
  • antioxidants butylated hydroxy anisole (BHA), butylated hydroxy toluene (BHT), ethoxyquin (6-ethoxy-1, 2-dihydro-2,2,4-trimethyl-quinoline), and the like
  • emulsifiers such as lecithin plasticisers, stabilisers, humectants like glycerin, sorbitol, polyethylene glycol, protective colloids, buffers, adjuvants can be included into the composition.
  • the particle size of the inner phase of the compositions according to the present invention is preferably less than 5 ⁇ m, more preferably less than 100 ⁇ m, e.g. 100 ⁇ m to 500 ⁇ m.
  • the particle size of the powderous compositions according to the present invention is typically in the range of 50-500 ⁇ m.
  • Active ingredients and encapsulating substances are dissolved in the solvent, preferably with stirring. If required, the solvent may be heated, if necessary under elevated pressure. Emulsifiers and other adjuvants may also be dissolved in the organic solvent.
  • the matrix compounds are dissolved in water, preferably with stirring. If required, the water may be heated. Emulsifiers and other water-soluble adjuvants may also be dissolved in the aqueous phase.
  • Emulsions may be prepared by any suitable method known to the person skilled in the art. Suitable known methods of preparation include emulsification with rotor-stator-systems, high pressure homogenisers or ultrasonic emulsification. To ensure good bioavailability, a small particle size of the active ingredient is required. Therefore, the particle size of the emulsion droplets should preferably be less than 5 ⁇ m, more preferably less than 1 ⁇ m, more preferably less than 0.5 ⁇ m.
  • Evaporation of the solvent may be performed by any suitable method known to the person skilled in the art. Suitable known methods of evaporation are e.g. thin-film evaporation or falling film evaporation, Evaporation may be done with or without reduced pressure at ambient or elevated temperature as required.
  • product forms described in this invention are preferably used as powders, other formulation types are also possible, e.g. liquid forms, pastes or pellets.
  • Powderous formulations are preferably produced by spray drying or by beadlet process as described e.g. in U.S. Pat. No. 6,444,227. Other known drying methods may also be used.
  • Solid forms could e.g. also be produced by extrusion of the emulsion together with a binder.
  • Liquid forms can be produced by using the emulsion after evaporation of the solvent.
  • This solution is added to the gelatine-sugar solution (a) to form the aqueous phase of the emulsion.
  • the pH of this solution is adjusted to 10.4 ⁇ 0.2 using a 20% w/w sodium hydroxide solution.
  • Both the aqueous and oil phases are heated to about 50°-55° C.
  • the oil phase is added slowly to the aqueous phase using both a high rate of mixing and a high shear force mixer.
  • the emulsion temperature is maintained at 55° C. while high speed shear mixing is continued for 15 minutes.
  • the temperature is gradually raised and mixing is continued until all the chloroform has been evaporated. This evaporation is usually completed when the temperature of the emulsion reaches about 75° C.
  • distilled water is added to the emulsion to maintain a viscosity appropriate to promote the evaporation procedure.
  • distilled water is added and thoroughly admixed with the emulsion to achieve an emulsion solids content and viscosity suitable for spray-drying. Viscosity of the spraying emulsion should be about 100 mPas
  • the emulsion is spray-dried under standard spray drying conditions using a spray drying tower.
  • Spraying conditions are suitably chosen in a way to keep product temperatur below 80° C.
  • distilled water is added and thoroughly admixed with the emulsion to achieve an emulsion solids content and viscosity suitable for spraying.
  • the emulsion is then sprayed into a bed of 1 kg of fluidised starch using a lab spraying-pan. Residual starch is removed by sieving.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Cosmetics (AREA)
  • Fodder In General (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to novel powderous, water-soluble compositions of fat-soluble substances and aqueous solutions or emulsions thereof, wherein the fat-soluble substance(s) are encapsulated as inner (discontinuous) phase within an outer (continuous) phase of a matrix substance.

Description

  • The present invention relates to novel compositions of fat-soluble substances. More particularly, the present invention relates to novel powderous, water-soluble compositions of fat-soluble substances and aqueous solutions or emulsions thereof. The novel compositions of this invention can be used as additives for food, beverages, animal feeds, cosmetics or drugs to incorporate said fat-soluble ingredients into such items. A particular feature of the novel compositions is the encapsulation of the fat-soluble substance(s) to form an inner (discontinuous) phase within an outer (continuous) phase of a matrix substance.
  • Thus, in one aspect, the present invention relates to novel compositions comprising
    • a) a matrix substance forming an outer (continuous) phase; and
    • b) an inner (discontinuous) phase within said matrix substance which comprises
    • b1) a fat-soluble physiologically active ingredient which is embedded in
    • b2) a physiologically acceptable encapsulating substance which is solid at room temperature and, together with said fat-soluble physiologically active ingredient, is homogeneously soluble in an organic solvent.
  • In a further aspect, the present invention relates to a process for the preparation of the novel compositions as defined above.
  • In still another aspect, the present invention relates to food or animal feed or supplement therefore, or pharmaceutical or cosmetic formulations comprising a composition as defined above.
  • The term “fat-soluble active ingredient” as used herein denotes any physiologically active ingredient that is soluble in lipids and insoluble or sparingly soluble in water. Examples of such fat-soluble active ingredients are fat-soluble vitamins, viz., vitamin A, D, E and K and derivatives thereof such as vitamin A esters, e.g. vitamin A acetate and palmitate, and vitamin E esters, e.g. tocopherol acetate; carotenoids and carotenoid derivatives, e.g., are α- or β-carotene, 8′-apo-β-carotenal, 8′-apo-β-carotenoic acid esters such as the ethyl ester, canthaxanthin, astaxanthin, astaxanthin esters, lycopene, lutein, zeaxanthin or crocetin and their derivatives; polyunsaturated fatty acids, e.g. eicosapentaenoic acid, docosahexaenoic acid, arachidonic acid and γ-linolenic acid and/or ethylester.
  • The term “encapsulating substance” denotes any edible substance, that is solid at application temperature, able to encapsulate the active ingredient and soluble together with the active ingredient in one common solvent. Preferably used are substances, which are commonly used as coating materials. More preferably used are synthetic or natural waxes or wax-like substances, or natural or synthetic edible polymers.
  • The wax or wax-like substance is preferably selected from among e.g. carnauba wax, candelilla wax, beeswax, rice bran wax, sugar cane wax, japan wax, esparto grass wax, cork wax, guaruma wax, ouricury wax, montan wax, spermaceti, lanolin, hydrated jojoba wax or paraffin wax, fats, hydrogenated fats, fatty acid monoglycerides, polypropylene glycol, polyethylene glycol, fatty acid esters, sucrose fatty acid esters, fatty acids, hydrocarbons and hydrogenated products thereof.
  • Natural edible polymers are preferably selected from modified (e.g. alkylated) carbohydrates (e.g. starch, pectin, alginate, carrageenan, furcellaran, chitosan, maltodextrin, dextrin derivatives), celluloses and cellulose derivatives (e.g. cellulose acetate, methyl cellulose, hydroxypropyl methyl cellulose), gums or modified (e.g. alkylated) gums (e.g. gum arabic, gum xanthan, gum guar, gum ghatti, gum karaya, gum tragacanth, locust bean gum, gellan gum), resins (e.g. shellac, wood rosin, and tree resins such as copal, damar and elemi), zein. Modification of these polymers may be necessary to improve solubility in organic solvents.
  • The synthetic polymer is preferably selected from among the synthetic waxes such as polyethylene and polypropylene waxes, coumarene-indene resins, polylactic acid (PLA) and poly(lactic/glycolic) acid (PLGA), acrylic polymers (methacrylic acid copolymers and ammonio methacrylate copolymers), polyorthoesters, polyphosphazenes, polyanhydrides, polyglycolide (PGA), poly(ε-caprolactone), polydioxanone, trimethylene carbonate, poly(β-hydroxybutyrate), poly(γ-ethyl glutamate), poly(DTH iminocarbonate), poly(bisphenol A iminocarbonate) and polycyanoacrylate, especially the acrylic polymers. Polyvinyl alcohol and polyvinylpyrrolidone polymers may also be used.
  • Preferred encapsulating substances for use in the invention are beeswax, carnauba wax, paraffin wax, polyethylene glycol and hydrogenated fats.
  • The ratio between active ingredient and encapsulating substance is determined by the amount of encapsulating substance, necessary to protect the active ingredient and by the target content of active ingredient within the formulation. Ratio of active ingredient: encapsulating substance may vary between about 10:1 to about 1:20 preferably between 1:3 and 3:1.
  • Ratio of (active ingredients+encapsulating substances): matrix is selected according to requirements of the specific formulation. Typical ratios could be e.g. 1:99 (1% forms), 1:9 (10% forms) or 1:1 (50% forms). The amount of matrix is determined by the amount necessary to stabilise the emulsion and to encapsulate the inner (oily) phase.
  • Matrix components are preferably selected from among carbohydrates (e.g. cellulose, starch, modified starch, dextrin, pectin, alginate, carrageenan, furcellaran, chitosan), gums (e.g. gum arabic, gum xanthan, gum guar, gum ghatti, gum karaya, gum tragacanth, locust bean gum, gellan gum), proteins (e.g. fish, poultry and mammalian gelatine, soy protein, pea protein, zein (from corn) wheat gluten, lupin protein, peanut protein, milk proteins or hydrolysed or modified milk proteins, especially casein or whey proteins, lignins and lignin derivatives (e.g. lignosulfonates, kraft lignins), celluloses and cellulose derivatives (e.g. carboxymethyl cellulose, carboxyethyl cellulose, hydroxypropyl cellulose).
  • Preferred matrix substances for use in the invention are gelatin, lignosulfonates, milk proteins or hydrolysed milk proteins, plant proteins or hydrolysed plant proteins, or modified starch, especially gelatine, casein and casein hydrolysates, soy protein, hydrolysates thereof, lignosulfonate, physically modified soy protein, starches and modified starches, especially octyl succinyl starch, pectins and carboxymethyl cellulose.
  • Particularly preferred are matrix substances which provide cold-water soluble compositions, such as lignosulfonate, fish gelatin, milk protein and hydrolysed plant proteins.
  • As solvent any organic solvent or solvent combination may be used that is able to dissolve active ingredient and encapsulating substance. Volatile Solvents and solvent combinations that are easy to evaporate from the emulsion are preferred. Examples for solvents are isopropanole, hexane, cyclohexane, acetone, methyl ethyl ketone, methylenchloride, chloroform, toluene, tetrahydrofurane, acetic acid ethyl ester.
  • As will be apparent from the foregoing, the compositions according to the invention comprise a matrix substance as a continuous phase wherein particles (droplets) of an encapsulating substance are distributed. Within said particles (droplets) of the encapsulating substance, the fat-soluble substance is distributed. Such compositions are distinguished from compositions wherein particles of the fat-soluble substance are distributed within a matrix substance (see, e.g. EP 564 989) or compositions wherein the fat-soluble substance is coated with a coating material or compositions according to JP 2004196673 wherein carotenoid-containg solutions are emulsified with coating solutions and subsequent freeze-drying thus producing powders wherein active ingredient and coating agent are distributed in different phases of the emulsion. The compositions of the present invention by virtue of their unique structure and mode of preparation provide superior stability on storage and application and show good bioavailability.
  • If necessary other components like antioxidants, butylated hydroxy anisole (BHA), butylated hydroxy toluene (BHT), ethoxyquin (6-ethoxy-1, 2-dihydro-2,2,4-trimethyl-quinoline), and the like, emulsifiers, such as lecithin plasticisers, stabilisers, humectants like glycerin, sorbitol, polyethylene glycol, protective colloids, buffers, adjuvants can be included into the composition.
  • The particle size of the inner phase of the compositions according to the present invention is preferably less than 5 μm, more preferably less than 100 μm, e.g. 100 μm to 500 μm. The particle size of the powderous compositions according to the present invention is typically in the range of 50-500 μm.
  • Active ingredients and encapsulating substances are dissolved in the solvent, preferably with stirring. If required, the solvent may be heated, if necessary under elevated pressure. Emulsifiers and other adjuvants may also be dissolved in the organic solvent.
  • The matrix compounds are dissolved in water, preferably with stirring. If required, the water may be heated. Emulsifiers and other water-soluble adjuvants may also be dissolved in the aqueous phase.
  • Organic and aqueous phase are mixed to form an emulsion. Emulsions may be prepared by any suitable method known to the person skilled in the art. Suitable known methods of preparation include emulsification with rotor-stator-systems, high pressure homogenisers or ultrasonic emulsification. To ensure good bioavailability, a small particle size of the active ingredient is required. Therefore, the particle size of the emulsion droplets should preferably be less than 5 μm, more preferably less than 1 μm, more preferably less than 0.5 μm.
  • Evaporation of the solvent may be performed by any suitable method known to the person skilled in the art. Suitable known methods of evaporation are e.g. thin-film evaporation or falling film evaporation, Evaporation may be done with or without reduced pressure at ambient or elevated temperature as required.
  • Although product forms described in this invention are preferably used as powders, other formulation types are also possible, e.g. liquid forms, pastes or pellets.
  • Powderous formulations are preferably produced by spray drying or by beadlet process as described e.g. in U.S. Pat. No. 6,444,227. Other known drying methods may also be used.
  • Solid forms could e.g. also be produced by extrusion of the emulsion together with a binder.
  • Liquid forms can be produced by using the emulsion after evaporation of the solvent.
  • The following Examples illustrate the invention further.
    • EXAMPLE 1
  • 2.5% Canthaxanthin Spray-Dried Powder.
  • (a) 330 g of gelatine, 279 g of sucrose, 0.75 g of sorbic acid and 1.50 g of sodium benzoate are added to 330 g of distilled water. The gelatine mixture is solubilised by hydrating overnight at about 50° C.
  • (b) The following solution is prepared:
  • Ascorbic acid 2.25 g
  • EDTA 0.75 g
  • Sodium lauryl sulfate 12.0 g
  • Distilled water 105.0 g
  • This solution is added to the gelatine-sugar solution (a) to form the aqueous phase of the emulsion. The pH of this solution is adjusted to 10.4 ±0.2 using a 20% w/w sodium hydroxide solution.
  • (c) An oil phase is prepared from
  • Canthaxanthin 23.3 g
  • Butylated hydroxy-toluene (BHT) 22.5 g
  • dl-α-tocopherol 22.5 g
  • Beeswax 23.3 g and
  • Chloroform 525 g
  • by first dissolving the BHT in dl-α-tocopherol by heating the mixture to 80° C. The solution is cooled to 55° C. and then mixed with the chloroform until a clear solution results. Canthaxanthin and beeswax are added to this solution under nitrogen atmosphere and dissolved.
  • Both the aqueous and oil phases are heated to about 50°-55° C. The oil phase is added slowly to the aqueous phase using both a high rate of mixing and a high shear force mixer. After the addition is completed, the emulsion temperature is maintained at 55° C. while high speed shear mixing is continued for 15 minutes. The temperature is gradually raised and mixing is continued until all the chloroform has been evaporated. This evaporation is usually completed when the temperature of the emulsion reaches about 75° C.
  • During the evaporation procedure distilled water is added to the emulsion to maintain a viscosity appropriate to promote the evaporation procedure.
  • After all the chloroform has been removed, distilled water is added and thoroughly admixed with the emulsion to achieve an emulsion solids content and viscosity suitable for spray-drying. Viscosity of the spraying emulsion should be about 100 mPas
  • The emulsion is spray-dried under standard spray drying conditions using a spray drying tower. Spraying conditions are suitably chosen in a way to keep product temperatur below 80° C.
    • EXAMPLE 2
  • 10% Canthaxanthin beadlet.
  • 15 g canthaxanthin and 15 g beeswax are dissolved together with 3 g Ethoxyquin in 600 ml chloroform. 75 g Na-Lignosulfonate is dissolved in 375 ml demineralised water. The pH of this solution is adjusted to 7.5 ±0.5 using a 20% w/w sodium hydroxide solution. The oil phase is added slowly to the aqueous phase using both a high rate of mixing and a high shear force mixer. After the addition is completed, the emulsion temperature is maintained at 50° C. while high speed shear mixing is continued for 15 minutes. The temperature is gradually raised and mixing is continued until all the chloroform has been evaporated. This evaporation is usually completed when the temperature of the emulsion reaches about 75° C. During the evaporation procedure, distilled water is added to the emulsion to maintain a suitable viscosity.
  • After all the chloroform has been removed, distilled water is added and thoroughly admixed with the emulsion to achieve an emulsion solids content and viscosity suitable for spraying. The emulsion is then sprayed into a bed of 1 kg of fluidised starch using a lab spraying-pan. Residual starch is removed by sieving.

Claims (14)

1. Compositions comprising
a) a matrix substance forming an outer (continuous) phase; and
b) an inner (discontinuous) phase within said matrix substance which comprises b1) a fat-soluble physiologically active ingredient which is embedded in b2) a physiologically acceptable encapsulating substance which is solid at room temperature and, together with said fat-soluble physiologically active ingredient, is homogeneously soluble in an organic solvent.
2. Compositions wherein the encapsulating substance is a wax or wax-like substance.
3. Compositions wherein the encapsulating substance is beeswax or carnauba wax.
4. Compositions wherein the encapsulating substance is a resin, a hardened fat, or a polymer.
5. Compositions as in claim 1 wherein the matrix substance comprises gelatin, a lignosulfonate, a milk protein or hydrolysed milk protein, a plant protein or hydrolysed plant protein, or modified starch.
6. Compositions as in claim 1 wherein the fat-soluble physiologically active ingredient is a carotenoid.
7. Compositions as in claim 6 wherein the carotenoid is astaxanthin or canthaxanthin.
8. Compositions as in claim 1 wherein the fat-soluble physiologically active ingredient is a polyunsaturated fatty acid.
9. Compositions as in claim 1 which are aqueous emulsions.
10. Compositions as in claim 1 which are solid compositions.
11. Compositions as in claim 10 which are cold-water soluble.
12. Compositions as in claim 1 which further comprise auxiliary agents such as antioxidants, stabilising and emulsifying agents.
13. Process for the preparation of a composition as claimed in claim 1 which comprises the steps of dissolving the fat-soluble physiologically active ingredient and the encapsulating substance in a common organic solvent for both substances to obtain an oily phase, emulsifying the oily phase with an aqueous solution of the matrix substance, evaporating the organic solvent, and, if desired, converting the emulsion into a solid state composition.
14. A food or animal feed or supplement therefor, or a pharmaceutical or cosmetic formulation comprising a composition as defined in claim 1.
US11/659,509 2004-08-19 2005-08-01 Novel Compositions of Fat-Soluble Substances Abandoned US20070248683A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04019678.4 2004-08-19
EP04019678 2004-08-19
PCT/EP2005/008297 WO2006018119A1 (en) 2004-08-19 2005-08-01 Novel compositions of fat-soluble substances

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/008297 A-371-Of-International WO2006018119A1 (en) 2004-08-19 2005-08-01 Novel compositions of fat-soluble substances

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/820,035 Division US8795715B2 (en) 2004-08-19 2010-06-21 Compositions of fat-soluble substances

Publications (1)

Publication Number Publication Date
US20070248683A1 true US20070248683A1 (en) 2007-10-25

Family

ID=35427847

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/659,509 Abandoned US20070248683A1 (en) 2004-08-19 2005-08-01 Novel Compositions of Fat-Soluble Substances
US12/820,035 Active US8795715B2 (en) 2004-08-19 2010-06-21 Compositions of fat-soluble substances

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/820,035 Active US8795715B2 (en) 2004-08-19 2010-06-21 Compositions of fat-soluble substances

Country Status (7)

Country Link
US (2) US20070248683A1 (en)
EP (1) EP1788897B2 (en)
JP (2) JP2008509945A (en)
KR (1) KR101398747B1 (en)
CN (2) CN1993060A (en)
ES (1) ES2587016T5 (en)
WO (1) WO2006018119A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120029088A1 (en) * 2010-07-27 2012-02-02 Jx Nippon Oil & Energy Corporation Anti-anxiety composition
US20120282367A1 (en) * 2010-01-15 2012-11-08 Kemin Industries, Inc. Rumen-Protected Lutein Product for Producing High-Lutein Dairy Products
CN114502009A (en) * 2019-10-11 2022-05-13 帝斯曼知识产权资产管理有限公司 Novel method for producing carotenoid feed additive

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2209388T3 (en) * 2007-09-19 2017-02-13 Borregaard As PROTECTION ANTIOXIDANT
JP2011521658A (en) * 2008-06-03 2011-07-28 ディーエスエム アイピー アセッツ ビー．ブイ． Composition of fat-soluble active ingredient containing gati gum
SI2432455T1 (en) * 2009-05-18 2015-04-30 Sigmoid Pharma Limited Composition comprising oil drops
CN107582526A (en) * 2009-08-12 2018-01-16 希格默伊德药业有限公司 Immune regulation composite comprising polymer substrate and oil phase
KR101782547B1 (en) * 2010-02-26 2017-09-27 유니버시다드 데 나바라 Nanoparticles for the encapsulation of compounds, preparation thereof and use of same
FR2967913A1 (en) * 2010-11-29 2012-06-01 Vetalis GALENIC COMPOSITION ADAPTED FOR NON-HUMAN ANIMAL DELIVERY, USES THEREOF, AND METHODS THEREOF
US9474715B2 (en) 2011-11-30 2016-10-25 Andreas Voigt Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition
KR101457912B1 (en) * 2012-03-26 2014-11-06 (주)바이오제닉스 Cosmetic composition having stabilized fat soluble active material and method for fabricating the same
KR101847947B1 (en) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 Stabilized modified release vitamin d formulation
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
JP6716582B2 (en) 2014-11-07 2020-07-01 サブリミティ・セラピューティクス・リミテッドＳｕｂｌｉｍｉｔｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ Composition containing cyclosporine
WO2018141791A1 (en) * 2017-02-03 2018-08-09 Dsm Ip Assets B.V. Improved process
KR102437686B1 (en) * 2017-05-25 2022-08-30 주식회사 엘지생활건강 Cosmetic composition comprising curd of uniform particle and method for manufacturing the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3110598A (en) * 1959-09-08 1963-11-12 Hoffmann La Roche Process of making a carotenoid preparation
US3886294A (en) * 1973-03-12 1975-05-27 Hoffmann La Roche Carotenoid coloring compositions and preparation thereof
US4522743A (en) * 1981-05-15 1985-06-11 Basf Aktiengesellschaft Preparation of finely divided pulverulent carotinoid and retinoid compositions
US5013569A (en) * 1990-05-21 1991-05-07 Century Laboratories, Inc. Infant formula
US6309677B1 (en) * 1998-03-24 2001-10-30 Amway Corporation Multi-carotenoid product

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US452273A (en) * 1891-05-12 Ammonia-absorber
NL251508A (en) * 1953-07-02 1900-01-01
DE1211911B (en) † 1959-09-08 1966-03-03 Hoffmann La Roche Process for the production of a carotenoid preparation particularly suitable for coloring food and feed
GB887883A (en) * 1959-09-08 1962-01-24 Hoffmann La Roche Manufacture of carotenoid preparations
JPS5649315A (en) * 1980-08-19 1981-05-02 Toyo Jozo Co Ltd Preparation of aspirin microcapsule pharmaceutical by underwater drying method
DE3702030A1 (en) † 1987-01-24 1988-08-04 Basf Ag POWDERED, WATER-DISPERSIBLE CAROTINOID PREPARATIONS AND METHOD FOR THE PRODUCTION THEREOF
US4880646A (en) * 1988-11-29 1989-11-14 Southwest Research Institute Encapsulated corn kernels and method of forming the same
NO903844L (en) * 1989-09-05 1991-03-06 Neophore Tech Inc MEDICINAL DELIVERY MIXTURES BASED ON BIOLOGICAL CELLS OR COMPONENTS THEREOF AND PROCEDURES.
ZA917708B (en) * 1990-09-28 1992-05-27 Hoffmann La Roche Beta-carotene emulsion composition
FR2695034B1 (en) 1992-09-01 1994-10-07 Oreal Cosmetic or pharmaceutical composition comprising in combination a peroxidase and a singlet anti-oxygen agent.
JPH07112980B2 (en) 1992-11-04 1995-12-06 株式会社スカイ・フード Active oxygen free radical scavenger
JPH08116887A (en) 1994-10-27 1996-05-14 Solar Japan Kk Method for culturing loach fry
US7097868B2 (en) * 2001-08-23 2006-08-29 Bio-Dar Ltd. Stable coated microcapsules
DE10205362A1 (en) * 2002-02-08 2003-08-21 Abbott Gmbh & Co Kg Process for the preparation of water-dispersible dry powder of water-poorly soluble compounds
JP3969652B2 (en) * 2002-12-16 2007-09-05 東洋酵素化学株式会社 Method for producing carotenoid-containing powder

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3110598A (en) * 1959-09-08 1963-11-12 Hoffmann La Roche Process of making a carotenoid preparation
US3886294A (en) * 1973-03-12 1975-05-27 Hoffmann La Roche Carotenoid coloring compositions and preparation thereof
US4522743A (en) * 1981-05-15 1985-06-11 Basf Aktiengesellschaft Preparation of finely divided pulverulent carotinoid and retinoid compositions
US5013569A (en) * 1990-05-21 1991-05-07 Century Laboratories, Inc. Infant formula
US6309677B1 (en) * 1998-03-24 2001-10-30 Amway Corporation Multi-carotenoid product

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120282367A1 (en) * 2010-01-15 2012-11-08 Kemin Industries, Inc. Rumen-Protected Lutein Product for Producing High-Lutein Dairy Products
US9717265B2 (en) * 2010-01-15 2017-08-01 Kemin Industries, Inc. Rumen-protected lutein product for producing high-lutein dairy products
US20120029088A1 (en) * 2010-07-27 2012-02-02 Jx Nippon Oil & Energy Corporation Anti-anxiety composition
CN114502009A (en) * 2019-10-11 2022-05-13 帝斯曼知识产权资产管理有限公司 Novel method for producing carotenoid feed additive

Also Published As

Publication number Publication date
KR20070043844A (en) 2007-04-25
WO2006018119A1 (en) 2006-02-23
US8795715B2 (en) 2014-08-05
KR101398747B1 (en) 2014-05-26
JP2014097999A (en) 2014-05-29
EP1788897B2 (en) 2019-06-19
ES2587016T3 (en) 2016-10-20
CN103082026A (en) 2013-05-08
CN1993060A (en) 2007-07-04
JP2008509945A (en) 2008-04-03
ES2587016T5 (en) 2020-02-27
EP1788897B1 (en) 2016-05-11
EP1788897A1 (en) 2007-05-30
US20100260811A1 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
US8795715B2 (en) Compositions of fat-soluble substances
JP6665385B2 (en) Extrusion method
US20060035871A1 (en) Pulverulent phytosterol formulations
KR102170339B1 (en) Novel coating system
JP2007503293A (en) Micro capsule
JPWO2009001786A1 (en) Bioactive substance-containing composition
CN1185433A (en) Carotenoid preparation capable of mixing with liquid and oil
JPWO2009001787A1 (en) Coenzyme Q10-containing composition
GB2298137A (en) Soft gelatin capsules
EP2925880B1 (en) Process for the production of discrete solid extruded particles
JP2010515446A (en) Oily composition
CN113575945B (en) Preparation method of nanoscale all-trans carotenoid dry powder
JP2002204673A (en) Solid preparation having multicore structure
KR20200007822A (en) Solid particles
JP4716982B2 (en) Powdered formulation of fat-soluble active ingredients
Contreras-López et al. Microencapsulation of Feed Additives with Potential in Livestock and Poultry Production: A Systematic Review
JP2017048129A (en) Soft capsules and production method thereof
NZ540473A (en) Pulverulent phytosterol formulations

Legal Events

Date Code Title Description
AS Assignment

Owner name: DSM IP ASSETS B.V., NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FUNDA, ELGER;REEL/FRAME:018915/0627

Effective date: 20061110

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION